Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Elevated blood cholesterol levels are a major risk factor for coronary artery disease, the leading cause of death worldwide. Probiotics have been investigated as potential cholesterol-lowering therapies, but no previous studies have assessed the effect of the probiotic yeast Saccharomyces boulardii on cholesterol levels in human volunteers. The objective of this study was to examine the effect of S. boulardii on serum cholesterol and lipoprotein particles in hypercholesterolemic adults. DESIGN: This study was a single-arm, open-label pilot study. SUBJECTS: Twelve hypercholesterolemic participants were recruited into the study; one dropped out. INTERVENTION: Participants took 5.6×10(10) colony forming unit (CFU) encapsulated S. boulardii (Saccharomyces cerevisiae var. boulardii CNCM I-1079) twice daily for an 8-week period. OUTCOME MEASURES: Fasting concentrations of cholesterol (total cholesterol, low-density lipoprotein-cholesterol [LDL-C], high-density lipoprotein-cholesterol [HDL-C], and triglycerides), lipoprotein particles (very-low-density lipoprotein-particle [VLDL-P], remnant lipoprotein particle [RLP-P], total LDL-P, LDL III-P, LDL IV-P, total HDL-P, and HDL 2b-P), and additional cardiovascular biomarkers (apo B-100, lipoprotein [a], high-sensitivity C-reactive protein, homocysteine, fibrinogen, and insulin) were measured at baseline, after 4 weeks, and after 8 weeks. RESULTS: Remnant lipoprotein particles decreased by 15.5% (p=0.03) over the 8-week period. The remaining outcome measures were not significantly altered. CONCLUSIONS: In this pilot study, 8 weeks of daily supplementation with S. boulardii lowered remnant lipoprotein, a predictive biomarker and potential therapeutic target in the treatment and prevention of coronary artery disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Jones, M. L., Martoni, C. J., & Prakash, S. (2012) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2012.126 · Cited by 277
Karpe, F., Boquist, S., Tang, R., Bond, G. M., de Faire, U., & Hamsten, A. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32331-2 · Cited by 174
Remnant lipoproteins as therapeutic targets
Havel, R. J. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200012000-00008 · Cited by 107 · cited 1×
“19 Remnant lipoproteins, like LDL, are considered highly atherogenic and are positively correlated with the severity and progression of CAD, independent of LDL-C levels.”
Nakamura, T., Obata, J.-E., Hirano, M., Kitta, Y., Fujioka, D., Saito, Y., Kawabata, K.-I., Watanabe, K., Watanabe, Y., Mishina, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.040 · Cited by 83 · cited 1×
“22,23 Because of their independent atherogenicity, remnant lipoproteins were previously identified by the National Cholesterol Education Program—Adult Treatment Panel III as a strong candidate for interventions aimed at reducing CAD risk.”
Cited by
In vitro bile salt hydrolase (BSH) activity screening of different probiotic microorganisms
Hernández-Gómez, J. G., López-Bonilla, A., Trejo-Tapia, G., Ávila-Reyes, S. V., Jiménez-Aparicio, A. R., & Hernández-Sánchez, H. (2021) · Foods · doi:10.3390/foods10030674 · Cited by 122
A Mini-Review of Human Studies on Cholesterol-Lowering Properties of Probiotics
Sivamaruthi, B. S., Kesika, P., & Chaiyasut, C. (2019) · Scientia Pharmaceutica · doi:10.3390/scipharm87040026 · Cited by 37
Karbownik, M. S., Kręczyńska, J., Kwarta, P., Cybula, M., Wiktorowska-Owczarek, A., Kowalczyk, E., Pietras, T., & Szemraj, J. (2020) · Nutrients · doi:10.3390/nu12051469 · Cited by 26
The Administration of Probiotics against Hypercholesterolemia: A Systematic Review
Sivamaruthi, B. S., Bharathi, M., Kesika, P., Suganthy, N., & Chaiyasut, C. (2021) · Applied Sciences · doi:10.3390/app11156913 · Cited by 20
“However, there are no significant changes in total cholesterol (TC), LDL-c, HDL-c, triglycerides (TG), TC/HDL-c, and non-HDL-c [43].”
BackgroundInfluential
Metadata
- Authors
- Ryan, J. J., Hanes, D. A., Schafer, M. B., Mikolai, J., & Zwickey, H.
- Venue
- The Journal of Alternative and Complementary Medicine
- Publisher
- SAGE Publications
- Published
- 2015-05
- Volume
- 21
- Issue
- 5
- Pages
- 288-293
- ISSN
- 1075-5535 (ISSN-L)
- 1557-7708
- OpenAlex
- W2066434022
- Cited by
- 35
- References
- 5
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.